title: [Anti-cancer monoclonal antibody].
authors.affiliation: First Department of Internal Medicine, Sapporo Medical University.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Sasaki
authors.forename: Tadao
authors.initials: T
authors.lastname: Ishida
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tsujisaki
authors.forename: Kohzoh
authors.initials: K
authors.lastname: Imai
mesh_terms: D000074323:Alemtuzumab; D000617:Aminoglycosides / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000068258:Bevacizumab; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D000079982:Gemtuzumab; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; C400149:Edrecolomab; D000068258:Bevacizumab; D000074323:Alemtuzumab; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D000079982:Gemtuzumab; C119496:tositumomab I-131; D000068878:Trastuzumab; D000068818:Cetuximab